Promoted Content
Promoted Content

Find Nephrology Clinical Drug Pipeline Developments & Deals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Terlipressin

            Therapeutic Area: Nephrology Product Name: Teripress

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Post-hoc, pooled analyses of three Phase 3 trials found HRS-1 patients treated with terlipressin was associated with less RRT up to Day 90 versus placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iptacopan

            Therapeutic Area: Nephrology Product Name: LNP023

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Data presented at the ASN 2020 Annual Meeting shows that investigational iptacopan effectively and safely reduced proteinuria in patients with C3 glomerulopathy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Finerenone

            Therapeutic Area: Nephrology Product Name: BAY 94-8862

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            The FIDELIO-DKD study, which evaluated the efficacy and safety of finerenone versus placebo when added to standard of care in patients with CKD and T2D, is the first large contemporary positive outcomes study in patients with CKD and T2D

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Nephrology Product Name: Farxiga

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            In the subgroup analysis, compared to placebo Farxiga showed a relative risk reduction of 37% for patients whose CKD was primarily driven by diabetic kidney disease; 57% for glomerulonephritis; and 42% for CKD of other or unknown causes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iptacopan

            Therapeutic Area: Nephrology Product Name: LNP023

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the alternative complement pathway, which is involved in the underlying pathophysiology of IgA nephropathy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Finerenone

            Therapeutic Area: Nephrology Product Name: BAY 94-8862

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            Finerenone significantly reduced the risk of the composite primary endpoint of time to kidney failure or renal death by 18% over a median duration of follow-up of 2.6 years when added to maximum tolerated dose of guideline-directed therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Empagliflozin

            Therapeutic Area: Nephrology Product Name: Jardiance

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            Jardiance reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction – with and without diabetes – regardless of CKD status at baseline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tenapanor

            Therapeutic Area: Nephrology Product Name: RDX5791

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kyowa Kirin

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia. Tenapanor is a phosphate absorption inhibitor currently under review by the FDA for the control of serum phosphorus in adult patients with CKD on dialysis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atrasentan Hydrochloride

            Therapeutic Area: Nephrology Product Name: ABT-627

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Atrasentan is a potent, selective endothelin A receptor (ETA) antagonist that has been evaluated in diabetic kidney disease patients in studies that demonstrated clinically significant and sustained reductions in proteinuria, as well as reduced risk of kidney function decline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KBP-5074

            Therapeutic Area: Nephrology Product Name: KBP-5074

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            The upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting showcases a pre-clinical study investigating the effect of KBP-5074 on aldosterone-mediated renal injury in the uninephrectomized SD rat CKD model.

            PharmaCompass